-
Something wrong with this record ?
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
S. Sembill, M. Ampatzidou, S. Chaudhury, M. Dworzak, K. Kalwak, A. Karow, A. Kiani, M. Krumbholz, M. Luesink, N. Naumann-Bartsch, B. De Moerloose, M. Osborn, KR. Schultz, P. Sedlacek, F. Giona, CM. Zwaan, H. Shimada, B. Versluijs, F. Millot, N....
Language English Country England, Great Britain
Document type Journal Article, Review
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Leukemia, Myeloid, Acute * MeSH
- Blast Crisis therapy MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy diagnosis MeSH
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Graft vs Host Disease * MeSH
- Prognosis MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on numerous clinical trials are available for chronic phase disease. However for CML in the blast phase (CML-BP), prognosis remains poor and treatment options are much more limited. The spectrum of treatment strategies for children and adolescents with CML-BP has largely evolved empirically and includes treatment principles derived from adult CML-BP and pediatric acute leukemia. Given this heterogeneity of treatment approaches, we formed an international panel of pediatric CML experts to develop recommendations for consistent therapy in children and adolescents with this high-risk disease based on the current literature and national standards. Recommendations include detailed information on initial diagnosis and treatment monitoring, differentiation from Philadelphia-positive acute leukemia, subtype-specific selection of induction therapy, and combination with tyrosine kinase inhibitors. Given that allogeneic hematopoietic stem cell transplantation currently remains the primary curative intervention for CML-BP, we also provide recommendations for the timing of transplantation, donor and graft selection, selection of a conditioning regimen and prophylaxis for graft-versus-host disease, post-transplant TKI therapy, and management of molecular relapse. Management according to the treatment recommendations presented here is intended to provide the basis for the design of future prospective clinical trials to improve outcomes for this challenging disease.
Comprehensive Cancer Center Erlangen EMN Erlangen Germany
Department of Pediatric Hematology and Oncology University Hospital Motol Prague Czech Republic
Department of Pediatric Hematology Oncology Aghia Sophia Children's Hospital Athens Greece
Department of Pediatric Hematology Oncology and BMT Wroclaw Medical University Wroclaw Poland
Department of Pediatrics Keio University School of Medicine Tokyo Japan
Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
Departments of Paediatric Oncology Haematology Poitiers University Hospital Poitiers France
Erasmus MC Sophia Children's Hospital Rotterdam the Netherlands
ITCC Hematological Malignancies Committee Rotterdam the Netherlands
Medizinische Klinik 4 Klinikum Bayreuth GmbH Bayreuth Germany
Pediatric Hemato Oncology Medical Faculty Technical University Dresden Dresden Germany
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
St Anna Kinderspital Department of Pediatrics Medical University Vienna Austria
Women's and Children's Hospital and Royal Adelaide Hospital Adelaide SA Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003947
- 003
- CZ-PrNML
- 005
- 20230425141013.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-023-01822-2 $2 doi
- 035 __
- $a (PubMed)36707619
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sembill, Stephanie $u Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany $u Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- 245 10
- $a Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations / $c S. Sembill, M. Ampatzidou, S. Chaudhury, M. Dworzak, K. Kalwak, A. Karow, A. Kiani, M. Krumbholz, M. Luesink, N. Naumann-Bartsch, B. De Moerloose, M. Osborn, KR. Schultz, P. Sedlacek, F. Giona, CM. Zwaan, H. Shimada, B. Versluijs, F. Millot, N. Hijiya, M. Suttorp, M. Metzler
- 520 9_
- $a Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on numerous clinical trials are available for chronic phase disease. However for CML in the blast phase (CML-BP), prognosis remains poor and treatment options are much more limited. The spectrum of treatment strategies for children and adolescents with CML-BP has largely evolved empirically and includes treatment principles derived from adult CML-BP and pediatric acute leukemia. Given this heterogeneity of treatment approaches, we formed an international panel of pediatric CML experts to develop recommendations for consistent therapy in children and adolescents with this high-risk disease based on the current literature and national standards. Recommendations include detailed information on initial diagnosis and treatment monitoring, differentiation from Philadelphia-positive acute leukemia, subtype-specific selection of induction therapy, and combination with tyrosine kinase inhibitors. Given that allogeneic hematopoietic stem cell transplantation currently remains the primary curative intervention for CML-BP, we also provide recommendations for the timing of transplantation, donor and graft selection, selection of a conditioning regimen and prophylaxis for graft-versus-host disease, post-transplant TKI therapy, and management of molecular relapse. Management according to the treatment recommendations presented here is intended to provide the basis for the design of future prospective clinical trials to improve outcomes for this challenging disease.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a blastická krize $x terapie $7 D001752
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $x diagnóza $7 D015464
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 12
- $a akutní myeloidní leukemie $7 D015470
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ampatzidou, Maria $u Department of Pediatric Hematology-Oncology, Aghia Sophia Children's Hospital, Athens, Greece
- 700 1_
- $a Chaudhury, Sonali $u Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 700 1_
- $a Dworzak, Michael $u St. Anna Kinderspital, Department of Pediatrics, Medical University, Vienna, Austria
- 700 1_
- $a Kalwak, Krzysztof $u Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Karow, Axel $u Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany $u Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- 700 1_
- $a Kiani, Alexander $u Medizinische Klinik IV, Klinikum Bayreuth GmbH, Bayreuth, Germany
- 700 1_
- $a Krumbholz, Manuela $u Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany $u Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany $1 https://orcid.org/0000000244160394
- 700 1_
- $a Luesink, Maaike $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
- 700 1_
- $a Naumann-Bartsch, Nora $u Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany $u Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
- 700 1_
- $a De Moerloose, Barbara $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium $1 https://orcid.org/000000022449539X
- 700 1_
- $a Osborn, Michael $u Women's and Children's Hospital and Royal Adelaide Hospital, Adelaide, SA, Australia $1 https://orcid.org/0000000212889930
- 700 1_
- $a Schultz, Kirk R $u Division of Hematology/Oncology/BMT, British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada $1 https://orcid.org/0000000200016438
- 700 1_
- $a Sedlacek, Petr $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Giona, Fiorina $u Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Zwaan, Christian Michel $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands $u ITCC Hematological Malignancies Committee, Rotterdam, the Netherlands
- 700 1_
- $a Shimada, Hiroyuki $u Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
- 700 1_
- $a Versluijs, Birgitta $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
- 700 1_
- $a Millot, Frederic $u Departments of Paediatric Oncology/Haematology, Poitiers University Hospital, Poitiers, France
- 700 1_
- $a Hijiya, Nobuko $u Division of Pediatric Hematology/Oncology/Transplant, Columbia University Irving Medical Center, New York, NY, USA
- 700 1_
- $a Suttorp, Meinolf $u Pediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany $1 https://orcid.org/0000000295228838
- 700 1_
- $a Metzler, Markus $u Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany. Markus.Metzler@uk-erlangen.de $u Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. Markus.Metzler@uk-erlangen.de $1 https://orcid.org/0000000245231676
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 37, č. 3 (2023), s. 505-517
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36707619 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141009 $b ABA008
- 999 __
- $a ok $b bmc $g 1924548 $s 1190156
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 37 $c 3 $d 505-517 $e 20230127 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20230418
